Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
82 "Obesity"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Article
Prevalence of Subclinical Hypothyroidism in a Non-Diabetic Young Female Population and Its Impact on Diabetes and Cardiometabolic Risk
Nawoda Hewage, Udaya Wijesekara, Rasika Perera
Received April 11, 2024  Accepted June 21, 2024  Published online November 5, 2024  
DOI: https://doi.org/10.3803/EnM.2024.2015    [Epub ahead of print]
  • 326 View
  • 24 Download
AbstractAbstract PDFPubReader   ePub   
Background
We evaluated the influence of subclinical hypothyroidism (SCH) on insulin resistance (IR), cardiometabolic risk, and obesity in childbearing-age women without diabetes.
Methods
This cross-sectional investigation included 282 women, aged 18 to 35 years, from rural and suburban Sri Lanka. Anthropometric and biochemical parameters, including IR and lipid/thyroid profiles, were recorded. Data were compared between SCH and euthyroidism (EU) for controls (normal weight) and cases (overweight/obese).
Results
The overall rates of SCH, EU, IR, and metabolic syndrome (MetS) were 40.42%, 59.57%, 73.40%, and 24.46%, respectively. Both controls and cases included individuals with SCH; overall, 168 participants (59.57%) had EU, while 114 (40.42%) exhibited SCH. IR was significantly associated with SCH in both weight groups (P<0.05). Among those with SCH, the odds ratios (ORs) for IR were >2 (95% confidence interval [CI], 0.45 to 3.87) in controls and >6 (95% CI, 3.52 to 8.41) in cases. Similarly, the ORs for MetS were >1 (95% CI, 0.38 to 4.16) in controls and >11 (95% CI, 8.73 to 15.01) in cases. Dyslipidemia and hypertriglyceridemia were significantly more prevalent in the SCH group (P<0.05). Women with SCH exhibited higher mean values for all obesity indices compared to their EU counterparts, surpassing normal thresholds (P<0.05). Among obesity measures, visceral adiposity index (VAI) demonstrated the highest area under the curve and sensitivity for assessing SCH and cardiovascular disease (CVD) risk.
Conclusion
SCH must be identified and managed in young women to help prevent diabetes and cardiometabolic disorders. VAI may aid in precisely detecting SCH and CVD.
Close layer
Review Articles
Diabetes, obesity and metabolism
Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
Endocrinol Metab. 2024;39(5):678-685.   Published online August 2, 2024
DOI: https://doi.org/10.3803/EnM.2024.2056
  • 1,254 View
  • 79 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
The prevalence of obesity in Korea has steadily increased over the past decade, reaching 38.4% in 2021. Notably, the rate of class II– III obesity, defined as a body mass index (BMI) of 30 kg/m2 or higher, exceeded 7% in the same year. Since January 2019, the National Health Insurance Service (NHIS) has provided coverage for bariatric surgery (BS) for eligible patients. Coverage is available for individuals with a BMI of 35 kg/m2 or higher, or those with a BMI of 30 kg/m2 or higher who also have obesity-related comorbidities. Additionally, partial reimbursement is offered for BS in patients with type 2 diabetes mellitus who have BMI values between 27.5 and 30 kg/m2. From 2019 to 2022, the NHIS recorded 9,080 BS procedures, with sleeve gastrectomy being the most commonly performed. The average percentage of weight loss 198±99.7 days post-surgery was 17.9%, with 80.0% of patients losing more than 10% of their body weight. This article presents the trends in obesity and BS in Korea.
Close layer
Diabetes, obesity and metabolism
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son, Soo Lim
Endocrinol Metab. 2024;39(2):206-221.   Published online April 16, 2024
DOI: https://doi.org/10.3803/EnM.2024.1940
  • 6,816 View
  • 519 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein–coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1–glucagon and GIP–GLP-1–glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.

Citations

Citations to this article as recorded by  
  • Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions
    Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi
    Biomedicines.2024; 12(8): 1630.     CrossRef
  • Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
    Katharina Gross, Christian Brinkmann
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients
    Bandar T. Alenezi, Nadra Elfezzani, Rukhsana Uddin, Hinali Patel, Sydney Chester, Ahmed Abdelmaksoud, Mohammad H. Hussein, Sawsan A. Zaitone, Manal S. Fawzy, Hani Aiash, Eman A. Toraih
    Journal of Clinical Medicine.2024; 13(16): 4896.     CrossRef
Close layer
Diabetes, obesity and metabolism
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
Endocrinol Metab. 2024;39(1):12-22.   Published online February 14, 2024
DOI: https://doi.org/10.3803/EnM.2024.1942
  • 8,979 View
  • 577 Download
  • 7 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions.

Citations

Citations to this article as recorded by  
  • New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
    Jorge E. Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno Grassi, Paulina Jofré, Hugo Verdejo, Monica Acevedo, Samuel Cordova, Luis Sanhueza, Douglas Greig
    International Journal of Molecular Sciences.2024; 25(8): 4407.     CrossRef
  • New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
    Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, Ludovica Simonini, Cristina Vassalle
    International Journal of Molecular Sciences.2024; 25(11): 6218.     CrossRef
  • Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
    Maria Antonietta Riemma, Elena Mele, Maria Donniacuo, Marialucia Telesca, Gabriella Bellocchio, Giuseppe Castaldo, Francesco Rossi, Antonella De Angelis, Donato Cappetta, Konrad Urbanek, Liberato Berrino
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity
    Se Hee Min
    The Journal of Korean Diabetes.2024; 25(2): 82.     CrossRef
  • Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
    Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang, Ming-Wei Wang
    Cell Discovery.2024;[Epub]     CrossRef
  • Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
    Michał Nicze, Adrianna Dec, Maciej Borówka, Damian Krzyżak, Aleksandra Bołdys, Łukasz Bułdak, Bogusław Okopień
    International Journal of Molecular Sciences.2024; 25(15): 8202.     CrossRef
  • Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology
    Karen Montecinos, Barbara Kania, David J. Goldberg
    Dermatological Reviews.2024;[Epub]     CrossRef
  • GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
    André J. Scheen
    Drugs.2024; 84(11): 1347.     CrossRef
  • Retatrutide
    Nathan Ramsbacher
    Clinical Diabetes.2024; 42(4): 579.     CrossRef
  • The power of three: Retatrutide's role in modern obesity and diabetes therapy
    Toufik Abdul-Rahman, Poulami Roy, Fatma Kamal Ahmed, Jann Ludwig Mueller-Gomez, Sarmistha Sarkar, Neil Garg, Victor Oluwafemi Femi-Lawal, Andrew Awuah Wireko, Hala Ibrahim Thaalibi, Muhammad Usman Hashmi, Andrew Sefenu Dzebu, Sewar Basheer Banimusa, Aayus
    European Journal of Pharmacology.2024; 985: 177095.     CrossRef
Close layer
Miscellaneous
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
Endocrinol Metab. 2023;38(6):619-630.   Published online November 21, 2023
DOI: https://doi.org/10.3803/EnM.2023.1814
  • 4,174 View
  • 137 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Metabolism is a dynamic network of biochemical reactions that support systemic homeostasis amidst changing nutritional, environmental, and physical activity factors. The circulatory system facilitates metabolite exchange among organs, while the endocrine system finely tunes metabolism through hormone release. Endocrine disorders like obesity, diabetes, and Cushing’s syndrome disrupt this balance, contributing to systemic inflammation and global health burdens. They accompany metabolic changes on multiple levels from molecular interactions to individual organs to the whole body. Understanding how metabolic fluxes relate to endocrine disorders illuminates the underlying dysregulation. Cancer is increasingly considered a systemic disorder because it not only affects cells in localized tumors but also the whole body, especially in metastasis. In tumorigenesis, cancer-specific mutations and nutrient availability in the tumor microenvironment reprogram cellular metabolism to meet increased energy and biosynthesis needs. Cancer cachexia results in metabolic changes to other organs like muscle, adipose tissue, and liver. This review explores the interplay between the endocrine system and systems-level metabolism in health and disease. We highlight metabolic fluxes in conditions like obesity, diabetes, Cushing’s syndrome, and cancers. Recent advances in metabolomics, fluxomics, and systems biology promise new insights into dynamic metabolism, offering potential biomarkers, therapeutic targets, and personalized medicine.

Citations

Citations to this article as recorded by  
  • Editorial: Tumor metabolism and programmed cell death
    Dan-Lan Pu, Qi-Nan Wu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Molecular subtypes of clear cell renal carcinoma based on PCD-related long non-coding RNAs expression: insights into the underlying mechanisms and therapeutic strategies
    Han Wang, Yang Liu, Aifa Tang, Xiansheng Zhang
    European Journal of Medical Research.2024;[Epub]     CrossRef
Close layer
Diabetes, obesity and metabolism
The Impact of Taurine on Obesity-Induced Diabetes Mellitus: Mechanisms Underlying Its Effect
Kainat Ahmed, Ha-Neul Choi, Jung-Eun Yim
Endocrinol Metab. 2023;38(5):482-492.   Published online October 17, 2023
DOI: https://doi.org/10.3803/EnM.2023.1776
  • 7,610 View
  • 239 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
This review explores the potential benefits of taurine in ameliorating the metabolic disorders of obesity and type 2 diabetes (T2D), highlighting the factors that bridge these associations. Relevant articles and studies were reviewed to conduct a comprehensive analysis of the relationship between obesity and the development of T2D and the effect of taurine on those conditions. The loss of normal β-cell function and development of T2D are associated with obesity-derived insulin resistance. The occurrence of diabetes has been linked to the low bioavailability of taurine, which plays critical roles in normal β-cell function, anti-oxidation, and anti-inflammation. The relationships among obesity, insulin resistance, β-cell dysfunction, and T2D are complex and intertwined. Taurine may play a role in ameliorating these metabolic disorders through different pathways, but further research is needed to fully understand its effects and potential as a therapeutic intervention.

Citations

Citations to this article as recorded by  
  • Enhancing metformin efficacy with cholecalciferol and taurine in diabetes therapy: Potential and limitations
    Gehan El-Akabawy, Nabil Eid
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Effect of a Very Low-Calorie Diet on Oxidative Stress, Inflammatory and Metabolomic Profile in Metabolically Healthy and Unhealthy Obese Subjects
    Neus Bosch-Sierra, Carmen Grau-del Valle, Christian Salom, Begoña Zaragoza-Villena, Laura Perea-Galera, Rosa Falcón-Tapiador, Susana Rovira-Llopis, Carlos Morillas, Daniel Monleón, Celia Bañuls
    Antioxidants.2024; 13(3): 302.     CrossRef
  • Association of Firmicutes/Bacteroidetes Ratio with Body Mass Index in Korean Type 2 Diabetes Mellitus Patients
    Kainat Ahmed, Ha-Neul Choi, Sung-Rae Cho, Jung-Eun Yim
    Metabolites.2024; 14(10): 518.     CrossRef
Close layer
Original Article
Diabetes, obesity and metabolism
Protective Effects of Melatonin in High-Fat Diet-Induced Hepatic Steatosis via Decreased Intestinal Lipid Absorption and Hepatic Cholesterol Synthesis
Hyungjune Ku, Yeonji Kim, Alvin Lyle Kim, Garam Lee, Youngsik Choi, Bukyung Kim
Endocrinol Metab. 2023;38(5):557-567.   Published online September 1, 2023
DOI: https://doi.org/10.3803/EnM.2023.1672
  • 3,660 View
  • 122 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The preventative effect of melatonin on the development of obesity and the progression of fatty liver under a high-fat diet (HFD) has been well elucidated through previous studies. We investigated the mechanism behind this effect regarding cholesterol biosynthesis and regulation of cholesterol levels.
Methods
Mice were divided into three groups: normal chow diet (NCD); HFD; and HFD and melatonin administration group (HFD+M). We assessed the serum lipid profile, mRNA expression levels of proteins involved in cholesterol synthesis and reabsorption in the liver and nutrient transporters in the intestines, and cytokine levels. Additionally, an in vitro experiment using HepG2 cells was performed.
Results
Expression of hepatic sterol regulatory element-binding protein 2 (SREBP-2), 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and low-density lipoprotein receptor (LDLR) demonstrated that melatonin administration significantly reduces hepatic cholesterol synthesis in mice fed an HFD. Expression of intestinal sodium-glucose transporter 1 (SGLT1), glucose transporter 2 (GLUT2), GLUT5, and Niemann-pick C1-like 1 (NPC1L1) demonstrated that melatonin administration significantly reduces intestinal carbohydrate and lipid absorption in mice fed an HFD. There were no differences in local and circulatory inflammatory cytokine levels among the NCD, HFD, and HFD+M group. HepG2 cells stimulated with palmitate showed reduced levels of SREBP, LDLR, and HMGCR indicating these results are due to the direct mechanistic effect of melatonin on hepatocytes.
Conclusion
Collectively, these data indicate the mechanism behind the protective effects of melatonin from weight gain and liver steatosis under HFD is through a reduction in intestinal caloric absorption and hepatic cholesterol synthesis highlighting its potential in the treatment of obesity and fatty liver disease.

Citations

Citations to this article as recorded by  
  • Influence of dark deprivation on the ultrastructure and mitochondrial apparatus of rat hepatocytes
    David A. Areshidze
    Morphology.2024; 161(3): 53.     CrossRef
Close layer
Review Article
Diabetes, Obesity and Metabolism
Big Data Articles (National Health Insurance Service Database)
Big Data Research in the Field of Endocrine Diseases Using the Korean National Health Information Database
Sun Wook Cho, Jung Hee Kim, Han Seok Choi, Hwa Young Ahn, Mee Kyoung Kim, Eun Jung Rhee
Endocrinol Metab. 2023;38(1):10-24.   Published online February 9, 2023
DOI: https://doi.org/10.3803/EnM.2023.102
  • 5,734 View
  • 292 Download
  • 18 Web of Science
  • 20 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
The Korean National Health Information Database (NHID) contains big data combining information obtained from the National Health Insurance Service and health examinations. Data are provided in the form of a cohort, and the NHID can be used to conduct longitudinal studies and research on rare diseases. Moreover, data on the cause and date of death are provided by Statistics Korea. Research and publications based on the NHID have increased explosively in the field of endocrine disorders. However, because the data were not collected for research purposes, studies using the NHID have limitations, particularly the need for the operational definition of diseases. In this review, we describe the characteristics of the Korean NHID, operational definitions of endocrine diseases used for research, and an overview of recent studies in endocrinology using the Korean NHID.

Citations

Citations to this article as recorded by  
  • Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study
    Kyoung Min Kim, Kyoung Jin Kim, Kyungdo Han, Yumie Rhee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1194.     CrossRef
  • Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data
    Jinyoung Kim, Bongseong Kim, Mee Kyoung Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
    Diabetes, Obesity and Metabolism.2024; 26(2): 567.     CrossRef
  • Diabetes severity and the risk of depression: A nationwide population-based study
    Yunjung Cho, Bongsung Kim, Hyuk-Sang Kwon, Kyungdo Han, Mee Kyoung Kim
    Journal of Affective Disorders.2024; 351: 694.     CrossRef
  • Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis
    Nobuyuki Horita, Kaoru Takase-Minegishi
    Journal of Thoracic Oncology.2024; 19(2): 348.     CrossRef
  • Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes
    Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(12): e2317.     CrossRef
  • Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea
    Hye-Sun Park, Kyoungsu Kim, Min Heui Yu, Ha Young Shin, Yumie Rhee, Seung Woo Kim, Namki Hong
    Journal of Bone and Mineral Research.2024; 39(6): 688.     CrossRef
  • All-cause and cause-specific mortality risks in individuals with diabetes living alone: A large-scale population-based cohort study
    Jae-Seung Yun, Kyungdo Han, Bongseong Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Yu-Bae Ahn, Yong-Moon Mark Park, Seung-Hwan Lee
    Diabetes Research and Clinical Practice.2024; 217: 111876.     CrossRef
  • Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
    Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
    Endocrinology and Metabolism.2024; 39(5): 678.     CrossRef
  • Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes
    Ji Yoon Kim, Sojeong Park, Minae Park, Nam Hoon Kim, Sin Gon Kim
    JAMA Network Open.2024; 7(11): e2443918.     CrossRef
  • Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6-year follow-up
    Ji Young Kang, Kyungdo Han, Seung-Hwan Lee, Mee Kyoung Kim
    Respiratory Research.2023;[Epub]     CrossRef
  • Research on obesity using the National Health Information Database: recent trends
    Eun-Jung Rhee
    Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 35.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
    Mee Kyoung Kim, Kyungdo Han, Hyuk-Sang Kwon, Soon Jib Yoo
    Endocrinology and Metabolism.2023; 38(4): 426.     CrossRef
  • Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
    Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
    Endocrinology and Metabolism.2023; 38(4): 436.     CrossRef
  • Is Thyroid Dysfunction Associated with Unruptured Intracranial Aneurysms? A Population-Based, Nested Case–Control Study from Korea
    Hyeree Park, Sun Wook Cho, Sung Ho Lee, Kangmin Kim, Hyun-Seung Kang, Jeong Eun Kim, Aesun Shin, Won-Sang Cho
    Thyroid®.2023; 33(12): 1483.     CrossRef
  • Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
    Joonyub Lee, Hun-Sung Kim, Kee-Ho Song, Soon Jib Yoo, Kyungdo Han, Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(5): 525.     CrossRef
  • Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
    Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    European Journal of Endocrinology.2023; 189(3): 363.     CrossRef
  • Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study
    Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • Long-Term Cumulative Exposure to High γ-Glutamyl Transferase Levels and the Risk of Cardiovascular Disease: A Nationwide Population-Based Cohort Study
    Han-Sang Baek, Bongseong Kim, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Sang-Ah Chang, Kyungdo Han, Jae-Seung Yun
    Endocrinology and Metabolism.2023; 38(6): 770.     CrossRef
  • Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
    Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku
    Endocrinology and Metabolism.2023; 38(6): 690.     CrossRef
Close layer
Original Articles
Diabetes, Obesity and Metabolism
Sleep Duration and the Risk of Type 2 Diabetes: A Community-Based Cohort Study with a 16-Year Follow-up
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Seung Ku Lee, Chol Shin, Nan Hee Kim
Endocrinol Metab. 2023;38(1):146-155.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1582
  • 4,072 View
  • 197 Download
  • 7 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
We aimed to investigate the moderating effects of obesity, age, and sex on the association between sleep duration and the development of diabetes in Asians.
Methods
We analyzed data from a cohort of the Korean Genome and Epidemiology Study conducted from 2001 to 2020. After excluding shift workers and those with diabetes at baseline, 7,407 participants were stratified into three groups according to sleep duration: ≤5 hours/night, >5 to 7 hours/night (reference), and >7 hours/night. The Cox proportional hazards analyses were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes mellitus (T2DM). Subgroup analyses were performed according to obesity, age, and sex.
Results
During 16 years of follow-up, 2,024 cases of T2DM were identified. Individuals who slept ≤5 h/night had a higher risk of incident diabetes than the reference group (HR, 1.17; 95% CI, 1.02 to 1.33). The subgroup analysis observed a valid interaction with sleep duration only for obesity. A higher risk of T2DM was observed in the ≤5 hours/night group in non-obese individuals, men, and those aged <60 years, and in the >7 hours/night group in obese individuals (HRs were 1.34 [95% CI, 1.11 to 1.61], 1.22 [95% CI, 1 to 1.49], and 1.18 [95% CI, 1.01 to 1.39], respectively).
Conclusion
This study confirmed the effect of sleep deprivation on the risk of T2DM throughout the 16-year follow-up period. This impact was confined to non-obese or young individuals and men. We observed a significant interaction between sleep duration and obesity.

Citations

Citations to this article as recorded by  
  • Attention to Innate Circadian Rhythm and the Impact of Its Disruption on Diabetes
    Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
    Diabetes & Metabolism Journal.2024; 48(1): 37.     CrossRef
  • Role of Sleep and Sleep Disorders in Cardiometabolic Risk: a Review and Update
    Shaden O. Qasrawi, Ahmed S. BaHammam
    Current Sleep Medicine Reports.2024; 10(1): 34.     CrossRef
  • Evaluating reliability in wearable devices for sleep staging
    Vera Birrer, Mohamed Elgendi, Olivier Lambercy, Carlo Menon
    npj Digital Medicine.2024;[Epub]     CrossRef
  • Replication Study of Genome Wide Association Study of Sleep Duration in Korean Association Resources Cohort
    Seok-Ho Cho, Seon-Ah Kim, Hyun-Seok Jin, Hong Sung Kim
    Biomedical Science Letters.2024; 30(2): 86.     CrossRef
  • Insights into optimal BMI from the GlasVEGAS study
    Chun-Kwan O, Juliana C. N. Chan
    Nature Metabolism.2024; 6(8): 1435.     CrossRef
  • Mechanisms, consequences and role of interventions for sleep deprivation: Focus on mild cognitive impairment and Alzheimer’s disease in elderly
    Upasana Mukherjee, Ujala Sehar, Malcolm Brownell, P. Hemachandra Reddy
    Ageing Research Reviews.2024; 100: 102457.     CrossRef
  • The Relationship Between the Risk of Type 2 Diabetes and Insomnia Severity and Sleep Duration in Academicians
    Tuğba Bilgehan, Esra Çalık Var
    Sağlık Bilimleri Üniversitesi Hemşirelik Dergisi.2024;[Epub]     CrossRef
  • All That Glitters Is Not Gold: The Same Sleep Time, but Different Diabetogenic Outcomes
    Bohye Kim, Obin Kwon
    Endocrinology and Metabolism.2023; 38(1): 78.     CrossRef
  • The Link Between Sleeping and Type 2 Diabetes: A Systematic Review
    Ali Darraj
    Cureus.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Association of Shift Work with Normal-Weight Obesity in Community-Dwelling Adults
Chul Woo Ahn, Sungjae Shin, Seunghyun Lee, Hye-Sun Park, Namki Hong, Yumie Rhee
Endocrinol Metab. 2022;37(5):781-790.   Published online October 25, 2022
DOI: https://doi.org/10.3803/EnM.2022.1532
  • 4,612 View
  • 206 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Shift work is associated with obesity and metabolic syndrome. However, this association in the normal-weight population remains unclear. This study aimed to investigate whether shift work is associated with normal-weight obesity (NWO).
Methods
From the nationally representative Korea National Health and Nutrition Examination Survey (KNHANES) dataset (2008 to 2011), 3,800 full-time workers aged ≥19 years with a body mass index (BMI) ≤25 kg/m2 were analysed. We defined NWO as BMI ≤25 kg/m2 and body fat percentage ≥25% in men and ≥37% in women. Working patterns were classified into “daytime,” “other than daytime,” and “shift.” Multivariable logistic regression analysis was performed to evaluate the relationship between shift work and NWO.
Results
Shift work was associated with higher odds of NWO than daytime work (adjusted odds ratio [aOR], 1.47; 95% confidence interval [CI], 1.04 to 2.09) and night/evening work (aOR, 1.87; 95% CI, 1.11 to 3.14) after adjustment for type of work, working hours, age, sex, BMI, 25-hydroxyvitamin D levels, homeostatic model assessment for insulin resistance, and other sociodemographic factors. In subgroup analyses, the association between shift work and NWO was more robust in those aged ≥60 years and those working ≥56 hours/week.
Conclusion
Shift work was associated with NWO in community-dwelling Korean adults, independent of age, sex, BMI, and other covariates.

Citations

Citations to this article as recorded by  
  • Association of Shift Work, Sociodemographic Variables and Healthy Habits with Obesity Scales
    Javier Tosoratto, Pedro Juan Tárraga López, Ángel Arturo López-González, Daniela Vallejos, Emilio Martínez-Almoyna Rifá, José Ignacio Ramirez-Manent
    Life.2024; 14(11): 1503.     CrossRef
  • Impaired Melatonin Secretion, Oxidative Stress and Metabolic Syndrome in Night Shift Work
    Sorina Hohor, Cristina Mandanach, Andreea Maftei, Corina Aurelia Zugravu, Marina Ruxandra Oțelea
    Antioxidants.2023; 12(4): 959.     CrossRef
  • Normal-Weight Obesity and Metabolic Syndrome in Korean Adults: A Population-Based Cross-Sectional Study
    Jeonghyeon Kim, Seamon Kang, Hyunsik Kang
    Healthcare.2023; 11(16): 2303.     CrossRef
  • You Can’t Avoid Shift Work? Then Focus on Body Fat Rather than Weight
    Eun Kyung Lee
    Endocrinology and Metabolism.2022; 37(5): 756.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
High Cardiorespiratory Fitness Protects against Molecular Impairments of Metabolism, Heart, and Brain with Higher Efficacy in Obesity-Induced Premature Aging
Patcharapong Pantiya, Chanisa Thonusin, Natticha Sumneang, Benjamin Ongnok, Titikorn Chunchai, Sasiwan Kerdphoo, Thidarat Jaiwongkam, Busarin Arunsak, Natthaphat Siri-Angkul, Sirawit Sriwichaiin, Nipon Chattipakorn, Siriporn C. Chattipakorn
Endocrinol Metab. 2022;37(4):630-640.   Published online August 5, 2022
DOI: https://doi.org/10.3803/EnM.2022.1430
  • 5,140 View
  • 132 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
High cardiorespiratory fitness (CRF) protects against age-related diseases. However, the mechanisms mediating the protective effect of high intrinsic CRF against metabolic, cardiac, and brain impairments in non-obese versus obese conditions remain incompletely understood. We aimed to identify the mechanisms through which high intrinsic CRF protects against metabolic, cardiac, and brain impairments in non-obese versus obese untrained rats.
Methods
Seven-week-old male Wistar rats were divided into two groups (n=8 per group) to receive either a normal diet or a highfat diet (HFD). At weeks 12 and 28, CRF, carbohydrate and fatty acid oxidation, cardiac function, and metabolic parameters were evaluated. At week 28, behavior tests were performed. At the end of week 28, rats were euthanized to collect heart and brain samples for molecular studies.
Results
The obese rats exhibited higher values for aging-related parameters than the non-obese rats, indicating that they experienced obesity-induced premature aging. High baseline CRF levels were positively correlated with several favorable metabolic, cardiac, and brain parameters at follow-up. Specifically, the protective effects of high CRF against metabolic, cardiac, and brain impairments were mediated by the modulation of body weight and composition, the lipid profile, substrate oxidation, mitochondrial function, insulin signaling, autophagy, apoptosis, inflammation, oxidative stress, cardiac function, neurogenesis, blood-brain barrier, synaptic function, accumulation of Alzheimer’s disease-related proteins, and cognition. Interestingly, this effect was more obvious in HFD-fed rats.
Conclusion
The protective effect of high CRF is mediated by the modulation of several mechanisms. These effects exhibit greater efficacy under conditions of obesity-induced premature aging.

Citations

Citations to this article as recorded by  
  • Interplay between obesity and aging on myocardial geometry and function: Role of leptin-STAT3-stress signaling
    Wei Jin, Fei Tu, Feng Dong, Qinqin Deng, Miyesaier Abudureyimu, Wei Yu, Guo-jun Cai, Jian-ming Pei, Zhaohui Pei, Jun Ren
    Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(2): 130281.     CrossRef
  • Epidemiological, mechanistic, and practical bases for assessment of cardiorespiratory fitness and muscle status in adults in healthcare settings
    Jaime A. Gallo-Villegas, Juan C. Calderón
    European Journal of Applied Physiology.2023; 123(5): 945.     CrossRef
  • Associations that Cardiorespiratory Fitness and Body Mass Index Loss Have with Deficit Accumulation Frailty
    KayLoni Olson, Denise K. Houston, Johnathan Ross, Rena R. Wing, Felicia R. Simpson, Ambarish Pandey, Michael P. Walkup, Mia Yang, Mark A. Espeland
    Medicine & Science in Sports & Exercise.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Association between the Blautia/Bacteroides Ratio and Altered Body Mass Index after Bariatric Surgery
Yoonhong Kim, Dooheon Son, Bu Kyung Kim, Ki Hyun Kim, Kyung Won Seo, Kyoungwon Jung, Seun Ja Park, Sanghyun Lim, Jae Hyun Kim
Endocrinol Metab. 2022;37(3):475-486.   Published online June 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.1481
Correction in: Endocrinol Metab 2022;37(4):701
  • 4,178 View
  • 142 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Current evidence support that the gut microbiota plays a potential role in obesity. Bariatric surgery can reduce excess weight and decrease the risk of life-threatening weight-related health problems and may also influence gut microbiota. In this study, we aimed to investigate the changes in gut microbiota before and after bariatric surgery and evaluate the association of the gut microbial shift and altered body mass index (BMI) after bariatric surgery.
Methods
Between January 2019 and July 2020, stools from 58 patients scheduled for bariatric surgery were collected. Six months after bariatric surgery, stools from 22 of these patients were re-collected, and the changes in gut microbiota before and after bariatric surgery were evaluated. In addition, the differences in gut microbiota between patients with severe obesity (BMI >35 kg/m2, n=42) and healthy volunteers with normal BMI (18.8 to 22.8 kg/m2, n=41) were investigated.
Results
The gut microbiota of patients who underwent bariatric surgery showed increased α-diversity and differed β-diversity compared with those before surgery. Interestingly, Blautia was decreased and Bacteriodes was increased at the genus level after bariatric surgery. Further, the Blautia/Bacteroides ratio showed a positive correlation with BMI. To validate these results, we compared the gut microbiota from severely obese patients with high BMI with those from healthy volunteers and demonstrated that the Blautia/Bacteroides ratio correlated positively with BMI.
Conclusion
In the gut microbial analysis of patients who underwent bariatric surgery, we presented that the Blautia/Bacteroides ratio had changed after bariatric surgery and showed a positive correlation with BMI.

Citations

Citations to this article as recorded by  
  • Modulation of the gut microbiome and Firmicutes phylum reduction by a nutraceutical blend in the obesity mouse model and overweight humans: A double‐blind clinical trial
    Victor Nehmi‐Filho, Jessica Alves de Freitas, Lucas Augusto Franco, Roberta Cristina Martins, José Antônio Orellana Turri, Aline Boveto Santamarina, Joyce Vanessa da Silva Fonseca, Ester Cerdeira Sabino, Bruna Carvalho Moraes, Erica Souza, Gilson Masahiro
    Food Science & Nutrition.2024; 12(4): 2436.     CrossRef
  • Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
    Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
    Endocrinology and Metabolism.2024; 39(5): 678.     CrossRef
  • Bile acids, fibroblast growth factor-19, and glucagon-like peptide-1 levels in the long term after bariatric surgery
    Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song
    Asian Journal of Surgery.2024;[Epub]     CrossRef
  • Natural emulsifiers lecithins preserve gut microbiota diversity in relation with specific faecal lipids in high fat-fed mice
    Chloé Robert, Armelle Penhoat, Leslie Couëdelo, Magali Monnoye, Dominique Rainteau, Emmanuelle Meugnier, Sofia Bary, Hélène Abrous, Emmanuelle Loizon, Pranvera Krasniqi, Stéphanie Chanon, Aurélie Vieille-Marchiset, François Caillet, Sabine Danthine, Huber
    Journal of Functional Foods.2023; 105: 105540.     CrossRef
  • Effects and action mechanisms of lotus leaf (Nelumbo nucifera) ethanol extract on gut microbes and obesity in high-fat diet-fed rats
    Zhang Yanan, Ma Lu, Zhang Lu, Huo Jinhai, Wang Weiming
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • First characterization of the intestinal microbiota in healthy Tunisian adults using 16S rRNA gene sequencing
    Ahlem Mahjoub Khachroub, Magali Monnoye, Nour Elhouda Bouhlel, Sana Azaiez, Maha Ben Fredj, Wejdene Mansour, Philippe Gérard
    FEMS Microbiology Letters.2023;[Epub]     CrossRef
  • Gut microbiota and nonalcoholic fatty liver disease
    Boyeon Kim, Bukyung Kim
    Kosin Medical Journal.2023; 38(3): 169.     CrossRef
  • Obésité et risque cardiovasculaire : le rôle de la chirurgie bariatrique dans la modulation du microbiote intestinal
    Davide Masi, Mickael Massicard, Karine Clément
    Nutrition Clinique et Métabolisme.2023; 37(2): 2S8.     CrossRef
  • The Related Metabolic Diseases and Treatments of Obesity
    Ming Yang, Shuai Liu, Chunye Zhang
    Healthcare.2022; 10(9): 1616.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Associations of Phthalate Metabolites and Bisphenol A Levels with Obesity in Children: The Korean National Environmental Health Survey (KoNEHS) 2015 to 2017
Moon Young Seo, Shinje Moon, Shin-Hye Kim, Mi Jung Park
Endocrinol Metab. 2022;37(2):249-260.   Published online April 7, 2022
DOI: https://doi.org/10.3803/EnM.2021.1235
  • 7,308 View
  • 171 Download
  • 11 Web of Science
  • 14 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Phthalates and bisphenol A (BPA) are synthetic chemicals widely used in daily life. This study investigated urinary phthalate and BPA levels in Korean children and their associations with obesity. Methods: A total of 2,351 children aged 3 to 17 years who participated in the Korean National Environmental Health Survey 2015 to 2017 were included. Urinary dilution was corrected using covariate-adjusted standardization (CAS). We examined the geometric mean (GM) concentrations of urinary phthalate metabolites, including di (2-ethylhexyl) phthalate (DEHP) metabolites (mono [2-ethyl-5-hydroxyhexyl] phthalate, mono [2-ethyl-5-oxohexyl] phthalate, and mono [2-ethyl-5-carboxypentyl] phthalate [MECPP]), mono-benzyl-phthalate (MBzP), mono (carboxyoctyl) phthalate (MCOP), mono (carboxy-isononyl) phthalate (MCNP), mono (3-carboxypropyl) phthalate, and mono-n-butyl-phthalate (MnBP), and BPA. We also analyzed the odds ratio (OR) for obesity according to the quartiles of each analyte. Results: The urinary GM levels of DEHP metabolites and MnBP were notably higher among Korean children than among American, Canadian, and German children. The CAS-applied GM concentrations of most analytes, except for MBzP, MCOP, and MCNP, were higher in children aged 3 to 5 years than in those aged 6 to 17 years. The OR for obesity in the highest quartile of MECPP was significantly higher than in the lowest quartile after adjusting for covariates. However, the other phthalate metabolites and BPA were not significantly associated with obesity. Conclusion: The concentrations of urinary DEHP metabolites and MnBP were higher in Korean children than in children in Western countries. Urinary MECPP exposure, but not other phthalates or BPA, showed a positive association with obesity in Korean children. Further studies are required to elucidate the causal relationships.

Citations

Citations to this article as recorded by  
  • Diethyl phthalate, a plasticizer, induces adipocyte inflammation and apoptosis in mice after long‐term dietary administration
    Shirsha Mondal, Soumyadeep Basu, Songita Ghosh, Suktara Guria, Sutapa Mukherjee
    Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
  • Urinary concentrations of phthalate/DINCH metabolites and body mass index among European children and adolescents in the HBM4EU Aligned Studies: A cross-sectional multi-country study
    Anteneh Desalegn, Tessa Schillemans, Eleni Papadopoulou, Amrit K. Sakhi, Line S. Haug, Ida Henriette Caspersen, Andrea Rodriguez-Carrillo, Sylvie Remy, Greet Schoeters, Adrian Covaci, Michelle Laeremans, Mariana F Fernández, Susana Pedraza-Diaz, Tina Kold
    Environment International.2024; 190: 108931.     CrossRef
  • Associations of prenatal and concurrent exposure to phenols mixture with anthropometric measures and blood pressure during childhood: A time-varying mixture approach
    Yiming Dai, Jiayun Ding, Zheng Wang, Boya Zhang, Qin Guo, Jianqiu Guo, Xiaojuan Qi, Dasheng Lu, Xiuli Chang, Chunhua Wu, Jiming Zhang, Zhijun Zhou
    Environmental Research.2024; 261: 119766.     CrossRef
  • Dietary bisphenols exposure as an influencing factor of body mass index
    Yolanda Gálvez-Ontiveros, Celia Monteagudo, María Giles-Mancilla, José Joaquín Muros, Vega Almazán, María Alba Martínez-Burgos, Cristina Samaniego-Sánchez, Inmaculada Salcedo-Bellido, Ana Rivas, Alberto Zafra-Gómez
    Environmental Health.2024;[Epub]     CrossRef
  • Endocrine-Disrupting Compounds in Urban Soils of Malaysia: Occurrence, Contamination, and Impacts on Health and the Environment
    Michael Lie, Joseph Kasongo, Elias Mtui, Rubiyatno, Jovale Vincent Tongco
    Tropical Aquatic and Soil Pollution.2024;[Epub]     CrossRef
  • Problematic issues of the impact of microplastics on the human body and the environment: A review
    Viktoria V. Pupykina, Irina N. Zakharova
    Pediatrics. Consilium Medicum.2024; (3): 230.     CrossRef
  • Di(2-ethylhexyl)phthalate and type 2 diabetes
    Sebolaishi Doris Makhubela, Ananias Hodi Kgopa, Matlou Phineas Mokgotho, Leshweni Jerry Shai
    Environmental Science: Advances.2024;[Epub]     CrossRef
  • Nontargeted metabolomic evidence for antagonism between tetracycline and its resistance bacteria underlying their obesogenic effects on Caenorhabditis elegans
    Zhuo Li, Di Wu, Zhenyang Yu, Changzheng Cui, Daqiang Yin
    Science of The Total Environment.2023; 859: 160223.     CrossRef
  • Prospective association between phthalate exposure in childhood and liver function in adolescence: the Ewha Birth and Growth Cohort Study
    Seonhwa Lee, Hye Ah Lee, Bohyun Park, Hyejin Han, Young Sun Hong, Eun Hee Ha, Hyesook Park
    Environmental Health.2023;[Epub]     CrossRef
  • Bisphenol A substitutes and childhood obesity at 7 years: a cross-sectional study in Shandong, China
    Minyan Chen, Cheng Lv, Shanyu Zhang, Lap Ah Tse, Xinyu Hong, Xi Liu, Yu Ding, Ping Xiao, Ying Tian, Yu Gao
    Environmental Science and Pollution Research.2023; 30(29): 73174.     CrossRef
  • Association between Di-2-ethylhexyl phthalate and nonalcoholic fatty liver disease among US adults: Mediation analysis of body mass index and waist circumference in the NHANES
    Youming He, Jun Zou, Ting Hong, Dan Feng
    Food and Chemical Toxicology.2023; 179: 113968.     CrossRef
  • Association between phthalate exposure and obesity risk: A meta-analysis of observational studies
    Qian Wu, Gang Li, Chen-Yang Zhao, Xiao-Lin Na, Yun-Bo Zhang
    Environmental Toxicology and Pharmacology.2023; 102: 104240.     CrossRef
  • Levels of Bisphenol A and its analogs in nails, saliva, and urine of children: a case control study
    Yolanda Gálvez-Ontiveros, Inmaculada Moscoso-Ruiz, Vega Almazán Fernández de Bobadilla, Celia Monteagudo, Rafael Giménez-Martínez, Lourdes Rodrigo, Alberto Zafra-Gómez, Ana Rivas
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Nontargeted Metabolomic Evidence for Antagonism between Tetracycline and its Resistance Bacteria Underlying Their Obesogenic Effects on Caenorhabditis Elegans
    Zhuo Li, Zhenyang Yu, Changzheng Cui, Daqiang Yin
    SSRN Electronic Journal .2022;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Stimulation of Alpha-1-Adrenergic Receptor Ameliorates Obesity-Induced Cataracts by Activating Glycolysis and Inhibiting Cataract-Inducing Factors
Yong-Jik Lee, Yoo-Na Jang, Hyun-Min Kim, Yoon-Mi Han, Hong Seog Seo, Youngsub Eom, Jong-suk Song, Ji Hoon Jeong, Tae Woo Jung
Endocrinol Metab. 2022;37(2):221-232.   Published online March 23, 2022
DOI: https://doi.org/10.3803/EnM.2021.1237
  • 4,864 View
  • 143 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Obesity, the prevalence of which is increasing due to the lack of exercise and increased consumption of Westernized diets, induces various complications, including ophthalmic diseases. For example, obesity is involved in the onset of cataracts.
Methods
To clarify the effects and mechanisms of midodrine, an α1-adrenergic receptor agonist, in cataracts induced by obesity, we conducted various analytic experiments in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a rat model of obesity.
Results
Midodrine prevented cataract occurrence and improved lens clearance in OLETF rats. In the lenses of OLETF rats treated with midodrine, we observed lower levels of aldose reductase, tumor necrosis factor-α, and sorbitol, but higher levels of hexokinase, 5’-adenosine monophosphate-activated protein kinase-alpha, adenosine 5´-triphosphate, peroxisome proliferator-activated receptordelta, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, superoxide dismutase, and catalase.
Conclusion
The ameliorating effects of midodrine on cataracts in the OLETF obesity rat model are exerted via the following three mechanisms: direct inhibition of the biosynthesis of sorbitol, which causes cataracts; reduction of reactive oxygen species and inflammation; and (3) stimulation of normal aerobic glycolysis.

Citations

Citations to this article as recorded by  
  • A review on drug repurposing applicable to obesity
    Feng Chen, Kai Jing, Zhen Zhang, Xia Liu
    Obesity Reviews.2024;[Epub]     CrossRef
  • α1-Adrenergic Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer’s Disease
    Dianne M. Perez
    International Journal of Molecular Sciences.2023; 24(4): 4188.     CrossRef
  • A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform
    Freek Haerkens, Charlotte Kikken, Laurens Kirkels, Monique van Amstel, Willemijn Wouters, Els van Doornmalen, Christof Francke, Samantha Hughes
    Heliyon.2022; 8(8): e10108.     CrossRef
Close layer
Namgok Lecture 2021
Diabetes, Obesity and Metabolism
The Influence of Obesity and Metabolic Health on Vascular Health
Eun-Jung Rhee
Endocrinol Metab. 2022;37(1):1-8.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.101
  • 11,067 View
  • 358 Download
  • 28 Web of Science
  • 35 Crossref
AbstractAbstract PDFPubReader   ePub   
The prevalence of obesity is rapidly increasing worldwide. Obesity should not be understood only as the accumulation of fat in the body, but instead as a phenomenon that exerts different effects on our health according to the place of fat deposition and its stability. Obesity is the starting point of most metabolic diseases, such as diabetes, hypertension, metabolic syndrome, sleep apnea, and eventually cardiovascular disease. There are different kinds of obesity, ranging from simple obesity to sarcopenic obesity. The main purpose of intervening to address obesity is to decrease the ultimate consequence of obesity—namely, cardiovascular disease. The main mechanism through which obesity, especially abdominal obesity, increases cardiovascular risk is the obesity-induced derangement of metabolic health, leading to the development of metabolic diseases such as diabetes, non-alcoholic fatty liver disease, and metabolic syndrome, which are the main initiators of vascular damage. In this review, I discuss the influence of various types of obesity on the risk of metabolic diseases, and how these diseases increase cardiovascular disease risk.

Citations

Citations to this article as recorded by  
  • Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
    Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
    European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118.     CrossRef
  • Severity of abdominal obesity and cardiometabolic diseases in US adults
    S. Wang, S. Shi, Y. Huang, H. Huang, V.W. Zhong
    Public Health.2024; 227: 154.     CrossRef
  • Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study
    Caiyun Zhang, Xiaoping Dong, Jun Chen, Fang Liu
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Anti-obesity effects of fucoidan from Sargassum thunbergii in adipocytes and high fat diet induced obese mice through inhibiting adipogenic specific transcription factor
    Hyo-Geun Lee, H.H.A.C.K. Jayawardhana, Fengqi Yang, D.P. Nagahawaththa, N.M. Liyanage, Kyung-Mo Song, Yun-Sang Choi, Seung-Hong Lee, You-Jin Jeon, Min-Cheol Kang
    Food Science and Human Wellness.2024; 13(3): 1608.     CrossRef
  • Association of a High Healthy Eating Index Diet with Long-Term Visceral Fat Loss in a Large Longitudinal Study
    Sunmin Park
    Nutrients.2024; 16(4): 534.     CrossRef
  • Ancistrocladus tectorius Extract Inhibits Obesity by Promoting Thermogenesis and Mitochondrial Dynamics in High-Fat Diet-Fed Mice
    Minju Kim, Jin Hyub Paik, Hwa Lee, Min Ji Kim, Sang Mi Eum, Soo Yong Kim, Sangho Choi, Ho-Yong Park, Hye Gwang Jeong, Tae-Sook Jeong
    International Journal of Molecular Sciences.2024; 25(7): 3743.     CrossRef
  • Biological Activity Evaluation of Olive, Grape, and Fig at Various Mixing Ratios
    Chan-Hwi Lee, So-Young Lee, Ae-Jung Kim
    Asian Journal of Beauty and Cosmetology.2024; 22(1): 91.     CrossRef
  • Investigation and Comparison of Maternal Pre-Pregnancy Body Mass Index Coupled with Gestational Weight Gain on Maternal–Fetal Complications Based on US and Chinese Guidelines: A Retrospective Study
    Wan-Ju Kung, Hsin-Yi Kuo, Ching-Feng Chang, Yeong-Hwa Zen, Ching-Chiang Lin
    Reproductive Sciences.2024; 31(8): 2379.     CrossRef
  • Docosahexanoic Acid Attenuates Palmitate-Induced Apoptosis by Autophagy Upregulation via GPR120/mTOR Axis in Insulin-Secreting Cells
    Seok-Woo Hong, Jinmi Lee, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2024; 39(2): 353.     CrossRef
  • Adipokine Modulation in Endometrial Hyperplasia by Polyunsaturated Fatty Acids
    Athuru Supriya, Ammu V. V. V. Ravi Kiran, Praveen Thaggikuppe Krishnamurthy
    Journal of Pharmacology and Pharmacotherapeutics.2024; 15(3): 237.     CrossRef
  • Association of osteoporosis with sarcopenia and its components among community-dwelling older Chinese adults with different obesity levels: A cross-sectional study
    Xing Yu, Yaqing Zheng, Yuewen Liu, Peipei Han, Xiaoyu Chen, Naiwen Zhang, Yejia Ni, Ziyi Zhou, Qi Guo
    Medicine.2024; 103(24): e38396.     CrossRef
  • Association between mixed exposure to per- and polyfluoroalkyl substances and metabolic syndrome in Korean adults: Data from the Korean National environmental health survey cycle 4
    Seung Min Chung, Kyun Hoo Kim, Jun Sung Moon, Kyu Chang Won
    International Journal of Hygiene and Environmental Health.2024; 261: 114427.     CrossRef
  • Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide
    Chuxiong Zheng, Yumeng Li, Xin Wu, Le Gao, Xiaoyi Chen
    Nutrients.2024; 16(14): 2354.     CrossRef
  • Impact of metabolic parameters and risk factors on surfactant proteins SP-A and SP-D in abdominal obesity
    K.Yu. Nikolaev, Ya.K. Lapitskaya, I.A. Kosarev, N.F. Dadashova
    Russian Journal of Preventive Medicine.2024; 27(7): 60.     CrossRef
  • Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study
    Astrid Lavens, Christophe De Block, Philippe Oriot, Laurent Crenier, Jean-Christophe Philips, Michel Vandenbroucke, An-Sofie Vanherwegen, Frank Nobels, Chantal Mathieu
    Diabetologia.2024; 67(12): 2678.     CrossRef
  • Association between lipid accumulation products and gallstones: an analysis of the National Health and Nutrition Examination Survey 2017–2020
    Huimin Wang, Xiaojia Feng, Qihui Huang, Xiaowei Zheng
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Lipid accumulation product, poverty income ratio, and bone mineral density in U.S. adults: a mediation analysis based on NHANES (2009–2020)
    Zihao Chen, Haobo Ye, Enli Li, Yuzhe Lin, Chen Jin, Lei Yang
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Epidemiology and Trends of Obesity and Bariatric Surgery in Korea
    Kyungdo Han, Jin-Hyung Jung, Su-Min Jeong, Mee Kyoung Kim
    Endocrinology and Metabolism.2024; 39(5): 678.     CrossRef
  • Assessment of Paraoxonase 1 and Arylesterase Activities and Lipid Profile in Bodybuilders: A Comparative Study of Physical Activity and Anthropometry on Atherosclerosis
    Hakim Celik, Mehmed Zahid Tuysuz, Yakup Aktas, Mehmet Ali Eren, Recep Demirbag
    Medicina.2024; 60(10): 1717.     CrossRef
  • Evaluation of Health Associations With Height‐Normalised Abdominal Body Composition Indices: A Single‐Centre Cross‐Sectional Study
    Yupeng Liu, Hangqian He, Keyu Qian, Yufeng Huang, Xuemei Ao, Xudong Shi, Binye Ruan, Ru Xue, Xiaoyi Fu, Shuran Wang
    Journal of Cachexia, Sarcopenia and Muscle.2024;[Epub]     CrossRef
  • Herbal appetite suppressants used to aid weight loss
    Sonia Malik, Sultana Patel, Dhvani H. Kuntawala, Gael N. N. Neba Ambe, Yannan Jin, Avninder S. Bhambra, Randolph R. J. Arroo
    Phytochemistry Reviews.2024;[Epub]     CrossRef
  • Association between lipid accumulation products and stress urinary incontinence: a cross-sectional study from NHANES 2005 to 2018
    JiHang Li, Dong Wang, Hu Tian, JianKun Yang, Hui Xia, WenBin Guo
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Impact of non-sugar sweeteners on metabolism beyond sweet taste perception
    Herbert Herzog, Lei Zhang, Luigi Fontana, G. Gregory Neely
    Trends in Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Mechanistic insights into dietary (poly)phenols and vascular dysfunction-related diseases using multi-omics and integrative approaches: Machine learning as a next challenge in nutrition research
    Dragan Milenkovic, Tatjana Ruskovska
    Molecular Aspects of Medicine.2023; 89: 101101.     CrossRef
  • Pharmacological Support for the Treatment of Obesity—Present and Future
    Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, Monika Różycka-Kosmalska, Tadeusz Pietras
    Healthcare.2023; 11(3): 433.     CrossRef
  • Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes
    Donna H. Ryan, John E. Deanfield, Stephan Jacob
    Cardiovascular Endocrinology & Metabolism.2023; 12(1): e0279.     CrossRef
  • Adipopenia is associated with osteoporosis in community-dwelling non-underweight adults independent of sarcopenia
    Seunghyun Lee, Kyoungmyoung Ko, Sungjae Shin, Hye Sun Park, Namki Hong, Yumie Rhee
    Archives of Osteoporosis.2023;[Epub]     CrossRef
  • Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism
    Shi-Yao Guo, Li-Yuan Wei, Bing-Bing Song, Yu-Tao Hu, Zhi Jiang, Dan-Dan Zhao, Yao-Hao Xu, Yu-Wei Lin, Shu-Min Xu, Shuo-Bin Chen, Zhi-Shu Huang
    European Journal of Medicinal Chemistry.2023; 260: 115729.     CrossRef
  • Short-Term L-Citrulline Supplementation Does Not Affect Blood Pressure, Pulse Wave Reflection, or Arterial Stiffness at Rest and during Isometric Exercise in Older Males
    Andrea Tryfonos, Filippos Christodoulou, George M. Pamboris, Stephanos Christodoulides, Anastasios A. Theodorou
    Sports.2023; 11(9): 177.     CrossRef
  • Skinfold Thickness as a Cardiometabolic Risk Predictor in Sedentary and Active Adult Populations
    Sughey González-Torres, Luis Miguel Anaya-Esparza, Gabriel Fermín Trigueros del Valle, Edgar Alfonso Rivera-León, Zuamí Villagrán, Sergio Sánchez-Enríquez
    Journal of Personalized Medicine.2023; 13(9): 1326.     CrossRef
  • Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study
    Ángel Arturo López-González, Bárbara Altisench Jané, Luis Masmiquel Comas, Sebastiana Arroyo Bote, Hilda María González San Miguel, José Ignacio Ramírez Manent
    Nutrients.2022; 14(14): 2795.     CrossRef
  • Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
    Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Predictive Roles of Basal Metabolic Rate and Body Water Distribution in Sarcopenia and Sarcopenic Obesity: The link to Carbohydrates
    Lizheng Guan, Tiantian Li, Xuan Wang, Kang Yu, Rong Xiao, Yuandi Xi
    Nutrients.2022; 14(19): 3911.     CrossRef
  • Metabolic risk factors in patients with comorbidity in Ufa primary health care
    O.V. Molchanova, A.V. Mamaeva, A.R. Dunayeva, Z.A. Lust, E.M. Faskhetdinova, R.N. Shepel, D.O. Orlov, L.M. Zhamalov, G.F. Andreeva, O.M. Drapkina
    Profilakticheskaya meditsina.2022; 25(9): 39.     CrossRef
  • Assessment of Vitamin D Levels in Relation to Statin Therapy in Elderly Hypertensive Patients with Comorbidities
    Kinga-Ilona Nyulas, Zsuzsánna Simon-Szabó, Zoltán Preg, Sándor Pál, Arundhati Sharma, Tünde Pál, Márta Germán-Salló, Enikő Nemes-Nagy
    Journal of Interdisciplinary Medicine.2022; 7(4): 88.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP